Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share more news from the company’s Phase 2a Study of Ifenprodil for idiopathic pulmonary fibrosis and chronic cough. Algernon telling Proactive the topline data tells them Ifenprodil is showing to be much more effective at reducing cough in patients. The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks and 39.5% at 12 weeks. The geometric mean awake cough counts were reduced by 30.2% at 4 weeks and 37.4% at 12 weeks.
Algernon Pharmaceuticals sees more positive date from Phase 2 study on Ifenprodil for IPF and Cough
